RIZZO, LORENZO
 Distribuzione geografica
Continente #
NA - Nord America 286
EU - Europa 165
AS - Asia 66
AF - Africa 6
SA - Sud America 4
OC - Oceania 1
Totale 528
Nazione #
US - Stati Uniti d'America 276
IT - Italia 82
SE - Svezia 41
IN - India 27
SG - Singapore 21
CN - Cina 13
CA - Canada 10
RO - Romania 9
DE - Germania 8
ES - Italia 6
TG - Togo 6
GB - Regno Unito 5
TR - Turchia 4
UA - Ucraina 3
AL - Albania 2
BG - Bulgaria 2
BR - Brasile 2
CH - Svizzera 2
SI - Slovenia 2
AR - Argentina 1
CL - Cile 1
IE - Irlanda 1
IL - Israele 1
LV - Lettonia 1
NL - Olanda 1
NZ - Nuova Zelanda 1
Totale 528
Città #
Chandler 41
Fairfield 35
Rome 21
Woodbridge 21
Wilmington 14
Singapore 12
Millbury 11
Princeton 11
Ashburn 9
Plano 9
Atella 8
San Paolo di Civitate 8
Cambridge 7
Toronto 7
Lomé 6
New York 6
Seattle 6
Andover 5
Beijing 5
Bremen 5
Columbus 5
Dearborn 5
Houston 5
Lawrence 4
Madrid 4
Tarquinia 4
Timisoara 4
Ann Arbor 3
Bari 3
Brookline 3
Cattolica 3
Fonte Nuova 3
Frankfurt am Main 3
Norwalk 3
Ottawa 3
Pavia 3
Pune 3
San Diego 3
Ankara 2
Barcelona 2
Chennai 2
Cwmbran 2
Des Moines 2
Istanbul 2
Ljubljana 2
Lucca 2
Marly 2
Melrose 2
Monopoli 2
Montale 2
Rimini 2
Santa Clara 2
Sofia 2
Springfield 2
Tirana 2
Turin 2
Watertown 2
Azor 1
Besana In Brianza 1
Bologna 1
Boston 1
Boydton 1
Brasília 1
Dallas 1
Dublin 1
Easton 1
Federal 1
Frascati 1
Guangzhou 1
Haverfordwest 1
Hebei 1
Jinan 1
Kunming 1
Nanchang 1
Naples 1
Napoli 1
Phoenix 1
Riga 1
Rotterdam 1
Santiago 1
Southend 1
St. Cloud 1
São Paulo 1
Trumbull 1
Wellington 1
West Wickham 1
Zhengzhou 1
Totale 379
Nome #
INDOMETHACIN AS FIRST LINE TREATMENT OF LANGERHANS CELL HISTIOCYTOSIS (LCH). A 20-YEAR EXPERIENCE OF A SINGLE CENTRE. 70
Specific guidelines including multidisciplinary approach is critical of management of Langerhans Cell Histiocytosis in adults 60
Intermittent Imatinib mesylate in children with chronic myeloid leukemia: results and outcome 57
EFFICACIA E SICUREZZA DELL’IMPIEGO DEI PICC IN PAZIENTI PEDIATRICI AFFETTI DA LEUCEMIA ACUTA: ESPERIENZA MONOCENTRICA 55
Applicazione della classificazione WHO 2016 IN 80 bambini e adolescenti con neoplasie mieloproliferative croniche 48
null 41
UTILITA’ DELLA TECNICA NEXT GENERATION SEQUENCING (NGS) NELL’IDENTIFICAZIONE DI GENI NON-DRIVER IN PAZIENTI CON MALATTIE MIELOPROLIFERATIVE CRONICHE (MMC) PEDIATRICHE WILD TYPE: ESPERIENZA DI UN SINGOLO CENTRO 40
EFFICACY OF INDOMETHACIN AS SALVAGE THERAPY IN CHILDREN AND ADULTS WITH LANGERHANS CELL HISTIOCYTOSIS WITH BONE INVOLVEMENT 40
null 38
Abstracts from the 36th Annual Meeting of the Histiocyte Society Virtual Sessions: October 1, 2020 and November 5, 2020 30
WHO 2016 classification in 80 children and adolescents with chronic myeloproliferative neoplasms 22
Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practice 12
Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients 11
null 10
Incidence of Clinically Significant (<= 10 g/dL) Late Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib 9
Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practice 9
Myelodysplastic Syndromes with Isolated 20q Deletion: A New Clinical-Biological Entity? 8
Identification of Predictive Factors for Overall Survival at Baseline and during Azacitidine Treatment in High-Risk Myelodysplastic Syndromes Treated in the Clinical Practice 6
Overall Survival and Response Rates after a 10-Year Follow-up of Chronic Myeloid Leukemia Patients in Chronic Phase Treated with Imatinib in a Real-Life Practice 2
Totale 568
Categoria #
all - tutte 1.801
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.801


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202092 0 0 1 3 7 18 16 15 12 11 2 7
2020/202130 3 4 0 0 4 0 1 3 10 0 1 4
2021/2022103 8 4 2 9 19 8 2 9 6 9 13 14
2022/2023159 26 25 11 17 17 15 1 9 20 3 5 10
2023/2024134 19 14 14 5 23 12 6 2 7 14 8 10
2024/202513 12 1 0 0 0 0 0 0 0 0 0 0
Totale 568